Precision Medicine Expert Dr. Paul Billings Rejoins Biological Dynamics, Inc. as Chief Executive Officer and Director

Internationally recognized authority on personalized health care to lead applications of company’s proprietary platforms and early disease detection assays

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a novel multiomic test company focused on detecting diseases at their earliest stages, announced the return of Paul Billings, MD, PhD, FACP, FACMGG to the company as Chief Executive Officer and Director. Previously, Dr. Billings has served in Advisor, Director, and Board Chairman roles before leaving to become Chief Medical Officer and Senior Vice President of Medical Affairs at Natera, Inc.

“We are elated at the return of Dr. Billings as Chief Executive Officer and Director of Biological Dynamics,” said Irwin M. Jacobs, ScD, Board Chairman. “Paul is an accomplished industry leader with significant expertise in genomics and clinical molecular medicine. He brings a track record of commercializing diagnostic products while navigating complicated regulatory environments. His leadership, knowledge, and experience motivating strong teams will help ensure that Biological Dynamics’ unique core technology is rapidly available to improve global health outcomes with reliable detection of early-stage cancers and other life-threatening diseases.”

Dr. Billings has devoted his life to studying and teaching medicine and genetics, while accelerating the use of a broad range of novel genomic technologies in clinical settings. Over his decades in healthcare, he has established key business partnerships, driving adoption of innovative discoveries and commercial success. His leadership is backed by notable achievements—physician, researcher, founder, senior executive or director of multiple public and private companies, and scientific advisor for government entities.

“Biological Dynamics has developed a highly differentiated and proprietary offering for patients and the biomedical community. I have returned to the company to lead its strategy and growth, and to demonstrate and apply its innovations. We intend to improve many aspects of disease detection and management, and, importantly, to help at-risk individuals and their families now with new critical data,” said Dr. Billings. “The existing team has generated important clinical evidence for the use of our platform in analyzing extracellular vesicles and exo-proteins. In addition to having received recognition from the FDA with a recent Breakthrough Device Designation, our Nature: Communications Medicine, in press peer-reviewed data are forthcoming. As we continue to add expertise and achieve milestones, we are increasingly optimistic about improving patient care and generating value for our shareholders.”

Dr. Billings has held academic appointments at Harvard University, U.C. San Francisco, Stanford University, and U.C. Berkeley; and served as a board-certified internist and medical geneticist at leading medical centers. His published doctoral studies at Harvard were supervised by Dr. Baruj Benacerraf who subsequently received the Nobel Prize in Medicine. In addition, he has served on the Scientific Advisory Board of the Food and Drug Administration (FDA), the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and as an appointee to the Secretary’s Advisory Committee on Genetics, Health, and Society at the Department of Health and Human Services. Previously, he has been Chief Medical Officer or Senior Physician at Laboratory Corporation of America Holdings, Life Technologies Corp, Thermo Fisher Scientific Inc., and Natera, Inc. He holds an MD and a PhD in Immunology from Harvard, and an Artium Baccalaureus, summa cum laude from U.C. San Diego.

About Biological Dynamics
Biological Dynamics, Inc. is an innovative biomedical science company committed to improving global health outcomes by detecting diseases at their earliest stages. The company's proprietary Verita™ platform simplifies access to biomarkers, nanoparticles, and nucleic acids, enabling differentiated multiomics applications. The company is applying its platform technology along with machine learning to detect several diseases, including cancer, in blood and other bodily fluids. It operates a CAP/CLIA accredited clinical laboratory in San Diego. For more information, please visit www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.

Contact:
Kevin Han
Chief Financial Officer
kevin.han@biodyn.io